Pieris AG and Daiichi Sankyo in €207 million deal to develop Anticalin compounds
This article was originally published in Scrip
Executive Summary
Pieris AG and Daiichi Sankyo have signed a deal that could be worth more than €207 million, under which Pieris will apply its proprietary Anticalin scaffold technology to discover novel Anticalins against two Daiichi Sankyo targets.